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1571 ABSTRACT 
The present invention provides an apparatus for separating 
a relatively large volume of blood into cellular and acellular 
fractions without the need for centrifugation. The apparatus 
comprises a housing divided by a fibrous filter into a blood 
sample collection chamber having a volume of at least about 
1 milliliter and a serum sample collection chamber. The 
fibrous filter has a pore size of less than about 3 microns, and 
is coated with a mixture of mannitol and plasma fraction 
protein (or an animal or vegetable equivalent thereof). The 
coating causes the cellular fraction to be trapped by the small 
pores, leaving the cellular fraction intact on the fibrous filter 
while the acellular fraction passes through the filter forh 
collection in unaltered form from the serum sample collec- 
tion chamber. 
3 Claims, 2 Drawing Sheets 
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METHOD AND APPARATUS FOR TEE 
COLLECTION STORAGE AND REAL TIME 
ANALYSIS OF BLOOD AND OTHER BODILY 
FLUIDS 
This application is a continuation of application Sa .  No. 
081247,187, filed May 19, 1994, now abandoned. 
ORIGIN OF THE INWNTION 
The invention described herein was made in the perfor- 
mance of work under a NASA contract and is subject to the 
provisions of Section 305 of the National Aeronautics and 
Space Act of 1958, Public Law 85-568 (72 Stat. 435; 42 
U.S.C. 2457). 
FIELD OF THE INVENTION 
The present invention provides a simple, inexpensive 
method and apparatus for passively separating cellular (or 
solid) and acellular fractions of clinically useful volumes of 
bodily fluids, for substantially simultaneously or subse- 
quently analyzing said bodily fluids for one or more 
analytes, and for prolonged preservation of said analytes. 
BACKGROUND OF THE INVENTION 
One of the primary means used to diagnose the state of a 
person’s health is to analyze the person’s blood or other 
bodily fluids for the presence or absence of “analytes” 
indicative of the person’s health. An “analyte” is any sub- 
stance contained in a bodily fluid for which either knowl- 
edge of the presence or concentration is desired for clinical 
or laboratory purposes, or for which the substance itself is 
retained and used for some other analytical or pharmaco- 
logical purpose. Analytes such as hormones, salts, enzymes, 
ketones, glucose, drugs, infectious agents. etc., indicate 
whether the person has contracted an infection and/or 
whether the person’s glands and/or other organs are func- 
tioning effectively. 
Ceaain bodily fluids, such as urine, saliva, semen, etc. can 
be obtained non-invasively, and analysis of such fluids can 
provide information about the state of a person’s health. 
Some analytes will be found only in catain bodily fluids, 
such as cerebrospinal fluid. However, the bodily fluid that 
typically gives the most complete picture of a person’s 
health is whole blood. 
One difiiculty encountered in analyzing many bodily 
fluids, such as whole blood. is that the “fluid” actually is 
composed of both solid and liquid components. For 
example, whole blood is composed of two fractions. One 
fraction is a “cellular” fraction, which includes the various 
types of blood cells and any other relatively “solid” matter 
found in the blood. The other fraction is an “acellular” 
fraction which consists of plasma or serum. Most of the 
“analytes” of interest are contained in the acellular fraction. 
In order to obtain the most accurate analysis of the blood, 
it is important to separate the analytes from the cellular 
fraction of the blood relatively quickly after the sample is 
drawn. Otherwise, the quantity and or quality of various 
analytes in the blood may be altered by the cellular fraction, 
e.g., by metabolism, release of intracellular content, and/or 
simple dilution. 
For similar reasons, the manner in  which the cellular 
fraction is separated from the acellular fraction of the blood 
is important in order to avoid contamination of the acellular 
fraction with components from the cellular fradon. For 
example, the separation process, itself, can cause the cells in 
the sample to lyse and release the intercellular content into 
the sample, thereby contaminating the sample. 
Methods for separating clinically useful volumes of blood 
generally require the blood to be collected, transferred into 
5 a glass  or plastic vial, and then centrifuged at high speed for 
a period of time. Centrifugation causes the cellular or solid 
fraction of the sample to collect at the bottom of the vial and 
the acellular supernatant plasma or serum to collect at the 
top of the vial. The supernatant then can be decanted and 
1o analyzed. Sometimes, the vial is provided with a medium 
density inert gel which-due to its specific gravity- 
substantially isolates the cellular from the acellular fraction 
when centrifuged, permitting the components to be frozen 
and stored together. 
Centrifugation and subsequent refrigeration of samples is 
l5 sufficient to preserve the integrity of a sample of blood or 
other bodily fluid for a sufFcient pericd of time in most 
cases. However, the process is cumbersome and expensive 
because it requires the blood or other sample either to be 
collected in a location having all of the proper equipment, or 
20 that the sample be refrigerated and transferred to a separate 
laboratory for further processing. Also, a substantial amount 
of time is required to obtain the results of the analysis. T h e  
may be critical to the life or health of the patient; therefore, 
a more rapid, less expensive, less cumbersome method is 
25 needed to analyze samples of blood andor other bodily 
fluids. 
Some methods exist for separating and analyzing very 
s m a l l  volumes of blood or other bodily fluids in situ. 
mically, these methods involve exposing the blood or other 
3o sample to a porous membrane or a porous mat of glass, fiber, 
or a polymer of plastic, protein, or carbohydrate, which traps 
the cellular components (or solids) but permits the plasma to 
flow through onto a paper or plastic strip where the plasma 
is reacted immediately with analytical reagents. 
Unfortunately, current methods and devices used for in 
situ analyses produce only a very small volume of serum or 
plasma which can be used only to measure one or a limited 
number of smal l  analytes, such as glucose, electrolytes, and 
pH. The sample of blood must be small-typically less than 
100 microliters. Because the entire sample is reacted &e- 
diately with the testing reagent(s), the entire sample is 
disposed of after it has been used for t h i s  limited purpose. 
None of the sample can be stored or used for any other 
testing. 
The in situ separation devices in current use often either 
do not separate the sample into cellular and acellular 
fractions, or they separate the serum into subfractions, 
thereby altering the biochemistry of the serum. Also, the 
type of analyses that can be pedormed using such devices 
50 typically is a one stage procedure. The analyte is mixed with 
one or a number of reagents simultaneously to produce a 
color change or chemical reaction. Because these devices 
lack a supportive matrix and a path through which the 
sample can pass before further analysis, they cannot be used 
55 to perform a multiple stage analysis capable of measuring 
complex molecules. such as hormones, enzymes, antibodies, 
or viral particles. In addition, the accuracy of such analyses 
is impaired by the presence of hemoglobin, which is freed by 
the hemolysis or rupture of red blood cells in the sample. 
The current methods used to test bodily fluids in situ also 
lack a convenient means for prolonged storage of viable 
samples. Currently, samples of bodily fluids must be refrig- 
erated at or below -20” C. in order to maintain the bio- 
chemical integrity of the sample. If the sample is to be tested 
65 for certain short lived or delicate analytes, preservatives 
and/or acids often must be added to preserve the integrity of 
the analytes. 
35 
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Some tests permit whole blood samples to be stored on 
blotting paper dried in air-for example, for neonatal pur- 
poses. However, these dried samples: can be used only to 
test qualitatively for a limited number of analytes; cannot be 
used for quantitative testing; and, only remain viable for 
testing for about two weeks. The short term viability for such 
dried samples largely results because the blood cells tend to 
rupture and contaminate the sample with intracellular con- 
tents during the drying process. The free hemoglobin 
released in  the rehydration process also interferes with many 
colorimetric assays. 
Some analytes, such as insulin, can be preserved in a 
desiccated state by freeze drying the analyte under a 
vacuum. Unfortunately, a significant number of analytes that 
can be preserved in  a desiccated state denature at some point 
during the process. Therefore. freeze drying of analytes is 
only of limited use to test for analytes that do not denature. 
An accurate, efficient process for in situ collection. 
separation, testing. and storage of bodily fluids, such as 
blood, which can be used for a broad spectrum of analytes 
would be highly desirable. 
SUMMARY OF THE INVENTION 
The present invention provides a simple, portable, rela- 
tively inexpensive apparatus for accurately and efficiently 
collecting, separating, testing, and even storing between 
about 1-20 d, preferably between about 1-10 ml, of blood 
or other bodily fluid in situ. The apparatus includes a 
collection chamber bounded on its sides by an opening in a 
sheet of material, preferably clear plastic, abutting a filter 
card. The filter card is made of fibrous material, preferably 
glass fiber material less than about a millimeter thick, having 
an average pore size of less than about 3 microns, more 
preferably less than about 1 micron. The fibrous material is 
treated with a carbohydratdprotein mixture which contains 
between about 140% wt/vol carbohydrate and about 
0.1-15% d v o l  non-specific protein, preferably between 
about 10-20% carbohydrate and about 5 4 %  protein. A 
preferred carbohydrate/protein mixture comprises about 
10% mannitol and about 6% albumin. The blood or other 
fluid moves through the filter card by capillary action aided 
by an absorbent matrix that has a high Klemm factor which 
abuts the filter card. The absorbent matrix andor filter card 
can be treated with a wide spectrum of test reagents. The 
speed, cleanliness, and efficiency of the separation process 
can be altered by: (a) changing the absolute concentration of 
the carbohydrate/protein mixture; (b) applying positive or 
negative pressure to one side of the filter; and/or (c) varying 
the relative density and pore size of the filter card and 
absorbent matrix. 
BRTEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is an exploded perspective view of the apparatus 
FIG. 2 is a compilation of the results from Examples 1 and 
of the invention. 
2. 
DETAILED DESCRETION OF THE 
INVENTION 
For ease in description. the method and apparatus of the 
present invention will be explained with reference to the 
separation and analysis of whole blood. However, the 
present invention is not limited to whole blood. The inven- 
tion also may be used to separate and test other bodily fluids 
in situ, whether of human or animal origin. Such bodily 
4 
fluids include, but are not limited to, blood. urine, saliva, 
tears, menstrual fluid, ascitic fluid, peritoneal fluid, joint 
fluid, cerebrospinal fluid, semen, transudate, or exudate. 
Knowing the particular body fluid and the type of analyte to 
5 be tested, a person of skiU in the art can determine the 
appropriate parameters in  light of the following description. 
Referring to FIG. 1, the apparatus 10 of the present 
invention comprises tubing 12 or other means for transfer- 
ring a bodily fluid of interest into a collection chamber 14 
10 formed by an opening in  a substantially flat or planar shell 
16. The shell 16, which is preferably made of a relatively 
inert clear plastic, has flanges 20 at its outer edges which 
extend toward a filter card 22. The surface area of the shell 
16 adjacent to the filter card 22 is slightly larger than the 
15 surface area of the filter card 22, so that, once the apparatus 
10 is assembled, the flanges 20 house the filter card 22 
substantially abutting the opening in the shell 16. The sides 
of the blood sample collection chamber 14 comprise the 
sides of the opening in the shell 16 and the bottom of the 
20 chamber 14 comprises the abutting filter card 22. The filter 
card 22 should be positioned so that the blood or other 
bodily fluid that is deposited in the collection chamber 14 
covers substantially the entire surface of the filter card 22 to 
infiltrate substantially the entire filter card 22. 
The filter card 22 may be composed of any suitable 
fibrous material having a large surface area, an appropriate 
density, and an appropriate average pore size. In  a preferred 
embodiment, the filter card 22 is made from glass fiber, 
which has a larger surface area than most fibers, permitting 
30 the use of a smaller volume of fibrous material to separate 
the components of the fluid. For whole blood, a desirable 
average pore size is less than about 3 u, preferably about 1 
u, and a desirable density, if the filter card is made from glass 
fiber, is a basis weight of about 465 @m2. Of course, the 
35 density will change with the weight of the fibrous materia 
however, lighter materials generally are preferred due to 
their portability. A preferred embodiment uses #32 Glass 
Fiber Filter, Catalog #08090, obtained from Schleicher and 
Schuell (Keene, N.H.). Other suitable materials for the filter 
card 22 include, but are not limited to, cellulose fibers, 
natural organic fibers, semi synthetic fibers, synthetic fibers, 
and hydrophilic polymeric gels. 
The filter card 22 should be treated with a protein/ 
45 carbohydrate mixture comprised of between about 1 4 0 %  
wt/vol carbohydrate mixed with 0.1-15% wt/vol non- 
specific protein, preferably about 10%-20% wt/vol carbo- 
hydrate and about 5-8-% wt/vol protein. A preferred 
embodiment uses about 10% wt/vol mannitol and about 6% 
Preferred carbohydrates include: monosaccharides, such 
as fructose, galactose, and glucose; disaccharides, such as 
mannitol, lactose, and sucrose; and, complex polymeric 
sugars, such as starch and glycogen. Preferred proteins 
55 include human plasma fractions, such as albumin, globulin. 
transport proteins, and low molecular weight animal and 
vegetable equivalents. The filter card 22 preferably is treated 
with the proteidcarbohydrate mixture by dipping the filter 
card 22 in a solution of the protein/carbohydrate solution 
Treatment of the filter card 22 with the protein/ 
carbohydrate mixture significantly improves the efficiency 
of separation and permits the separation of relatively large 
volumes of whole blood up to about 20 milliliters. The 
65 amount of blood that can be separated is limited only by the 
size of the apparatus 10. The relative proportion, absolute 
amount, and composition of the carbohydratdprotein mix- 
25 
5o wt/vol albumin. 
60 and then air drying the filter card 22. 
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ture provides variable and optimal control of the separation The transfer of such fluid into the collection chamber 14 can 
process while preventing cell lysis. The speed, cleanliness, be aided, if desired, by aspiration with a syringe using an 
and efficiency of the separation process can be altered by: (a) aspiration port 28 in the back plate 24. The asphation port 
changing the absolute concentration of carbohydrate and/or 28 may have any suitable construction which is compatible 
protein in the mixture; (b) applying positive or negative 5 with an aspiration syringe. For example, the port may be a 
pressure to one side of the filter card 22; and/or (c) varying female Luer port which extends away from the body of the 
the relative size of p r e s  in the filter card 22 and absorbent apparatus 10. The aspiration port 28 preferably should be 
matrix 30. sealed using any known means capable of maintaining the 
The “efficiency” of the process generally refers to the water tight seal within the apparatus 10. but also permitting 
ability of the process to extract the largest percentage of disruption of the seal if aspiration is desired. 
available serum or acellular fluid contained in a particular The separation process may be continued until the filter 
sample. The apparatus and method of the present invention card 22 and/or the absorbent matrix 30 is filled. The blood 
normally recovers approximately 80-100% of the serum in or other bodily fluid is drawn by the high Klemm factor of 
whole blood. The “cleanliness” of the process refers to how the absorbent matrix 30 and passes through the filter card22 
effectively the process screens the serum or fluid of cells 15 by capillary action independent of gravity. The passive 
andor other solids. Generally, increasing the concentration operation of the apparatus 10 is advantageous because one 
of carbohydrate in the solution used to coat the filter card 22 of the contemplated uses for the invention is to collect, 
increases the efficiency and cleanliness of the separation but separate, and store blood or other bodily fluids during space 
decreases the speed of the separation. Therefore, a higher flight in the absence of gravity. In addition, capillary action 
concentration of carbohydrate, in the range of 10-20% 2o does not require a centrifuge or other cumbersome equip- 
wthol, normally is preferred as long as the analytes to be ment to separate the bodily fluid. Compared to the glass or 
tested will survive for about 30 minutes to about 1 hour. plastic vials and powered equipment required to separate 
Some analytes are extremely delicate and/or have extremely body  fluids by centrifuge, the apparatus 10 of the present 
short half lives. In order to test for such analytes, it may be invention is extremely portable. 
necessary lower the concentration of carbohydrate some 25 The absorbent matrix 30 preferably is supported in a 
what and accept a lower level of efficiency and cleanliness frame 32 made of any suitable material, preferably a rela- 
of the process. In some cases, a preserving agent may be tively inert clear plastic. The absorbent matrix 30 and the 
added to to the sample before beginning the separation back plate 24 preferably are provided with pull-tabs 34. 
process in order to preserve such andytes. Another way to When the filtration process is complete, the pull-tabs 34 
preserve some short lived analytes might be to include an 3o permit the removal of the absorbent matrix 30 from the 
antibody for the analyte on the absorbent matrix 30. The apparatus 10 without the need for direct contact which could 
binding of the analyte to the specific antibody, itself, may contaminate the absorbent matrix 30. 
preserve the analyte for further analysis. The absorbent matrix 30 and/or the filter card 22 may be 
After passing through the filter card 22, the plasma impregnated with any number of suitable reagents to test for 
fraction reaches a serum sample collected chamber which 35 particular analytes, including well known reagents used to 
may contain an absorbent matrix 30 preferably positioned in conduct specific antibody mediated assays, enzyme medi- 
direct contact with the filter card 22. The absorbent matrix ated assays, ligand mediated assays, and binding resins. As 
30 should be made from a material having a relatively high already alluded to, the filter card 22 and/or the absorbent 
“Klemm” factor, on the order of at least about 15, preferably matrix 30 also may be impregnated with specific chemicals 
about 3670. The higher the Klemmfador, the more passive 40 andor antibod(ies) which will preserve delicate or short 
force will be exerted on the sample to draw the Sample lived analytes for later extraction and analysis. Also, because 
through the filter card 22. The Klemm factor should be as the separation process can begin substantially simulta- 
high as possible without causing blood cells or other solid neously with the collection of the bodily fluid, biochemical 
matter to flow through the lilter card 22. In  a preferred changes in the concentration and/or structure of analytes due 
embodiment, the absorbent matrix 30 is Plasma Card Grade 45 to the presence of a cellular fraction are minimized or 
900, a cellulose filter having a Klemm factor of about 64, eliminated For example, the cellular fraction is not available 
obtained from Schleicher & Schuell (Product #56630). to consume glucose or other consumable analytes in the 
Other suitable materials for the absorbent matrix 30 include, sample. The preservation of short lived and/or delicate 
but are not limited to, sepharose gel, agar, and glass fiber analytes can be enhanced by prechilling the apparatus 10 
matting. 50 before use, and/or by transferring the apparatus 10 to a 
Once assembled, the flanges 20 adhere to a back plate 24, cooled environment as soon as possible during or after the 
preferably fonning a substantially water tight seal around separation process. 
the filter card 22 and absorbent matrix 30 using any suitable The absorbent matrix 30 may be used and/or stored in a 
means known in the a r t  Although a substantially water tight number of different ways. In a preferred embodiment. the 
seal is preferred, the invention does not require a tightly 55 absorbent matrix 30 is dried by subjecting the matrix to a 
sealed filter in a pressure vessel, as do many other tech- flow of dry air which preferably should not exceed body 
niques. temperature. Above about 40” C., enzymes and other deli- 
The tubing 12, or other means used to deposit the bodily cate analytes on the absorbent rnatrix 30 tend to degrade. 
fluid in the collection chamber 14, may be directly con- Once dried, the absorbent matrix can be placed in a con- 
nected to a venous catheter or other access or collection port 60 tainer with a desiccant and an oxygen scavenger, such as an 
for blood or another bodily fluid. In this way, the fluid activated cuprous compound, to reduce the water content 
sample can be immediately deposited in the collection and oxygen tension in the surrounding atmosphere. 
chamber 14 and analyzed substantidy as it is collected. If Preferably, the oxygen content of the air sunrounding the 
the fluid is blood, direct transfer of the fluid to the collection sample should be maintained as close as possible to 0%. The 
chamber 14 obviates the need for anticoagulation. If tubing 65 sample also preferably should be isolated from light. 
is used, the tubing 12 preferably is engaged with a plate 18 Otherwise, the sample may be stored in ambient conditions. 
which has a suitable adapter 26, such as a male Luer port. The addition of standard anti-peptidase chemicals, 
5,665,238 
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antioxidants, and/or preservatives will protect certain ana- invention. After insertion of an appropriate venous cannula 
lytes whose concentrations may be altered in the drying or butterfly using standard procedures, the vacutainer 
process. Compared to other available methods for storing adapter was attached and two 5 ml samples of whole blood 
such samples, the procedures required to preserve and store were collected into two 5 ml vacutainer tubes. The venous 
the absorbing matrix 30 in robust condition are simple, 5 line was occluded and the vacutainer adapter removed. 
inexpensive, and portable. A blood collection device was attached to the cannula and 
Storing bodily fluids on the absorbent matrix 30 can inspected visually while it was filling. The operator was able 
preserve a broad range of the analytes for clinical and to look through the clear casing of the blood collection 
research purposes for extended periods of at least days to device and observe the filling of the chamber with blood. 
weeks. In fact, some analytes which are very dif€icult to 10 After the chamber filled completely, the venous line again 
preserve by freezing have been preserved using the present was occluded. The process was repeated until five blood- 
invention. collection devices were filled. The cannula then was sealed 
The use of a clear plastic shell 16. flanges 20, and back or removed. 
plate 24 will result in an additional advantage. The clear The collection devices were fitted with Velcro tabs to 
plastic will permit the filtration process to be observed. An l5 anchor them to the working area and set aside for about one 
end point for the process can be selected by choosing an hour. After completion of the blood collection, the blood 
acceptable time, determined p&ly by the design of the filter collection devices were inspected, and any droplets floating 
and the fluid being absorbed or by watching the area of free in the chamber behind the absorbent material noted. If 
discoloration of the absorbing matrix 30 through the back free fluid was present, the blood-collection device was 
plate 24. Furthermore, the chemical testing reagent(s) can be moved to the drop until the drop was absorbed onto the 
impregnated onto either the absorbent matrix 30 or both the absorbent material. When no free droplets were visible, the 
absorbent matrix 30 andor the filter card 22 and then a color blood collection device was opened and the absorbent 
change, agglutination, or other process taking place on the material containing the plasma was removed by pulling the 
absorbing matrix 30 can be observed through the clear tab. The casing of the blood-collection device was closed 
plastic. In addition, the assay may be by direct fluoroscopy, 25 and the entire unit was discarded. The card then was 
spectroscopy, or thermal or electrical impedance. The latter transferred into the drying box where it slid down into 
will require the incorporation of appropriate electrodes into grooves that supported and spaced the cards. The process 
the plastic back plate. was repeated for all 5 cards. A fan in the drying box was 
The apparatus 10 also can be adapted so that the results turned on and the cards were dried in a flow of room air for 
can be quantified. For example, a line of reagent “dots” may 30 about 2 hours. At the end of the 2 hours, the fan was turned 
be engineered into the apparatus 10 so that the dots react to off and the dessicant and oxygen scavenger was activated by 
a specific concentration of analyte. After reaction, the dots removing the protective cover for these materials. The lid of 
may be compared to a scale which will quantify the results the drying box was then closed and the cards were left in the 
of such reaction. For example, the dots could be engineered box for storage. 
to change color either absolutely or to an intensity that The two vacutainer samples were placed in a centrifuge 
relates to the concentration of a particular analyte in the and cells and plasma were separated according to estab- 
sample. The color of the dots after the reaction could be used lished procedure. The vacutainers then were placed in 
to extrapolate the concentration of the analyte present in the approximately -20” C. refrigeration and the time and date 
whole blood, e.g., by comparison to a color scale which may 4o recorded. The entire unit was stowed for the remainder of the 
be separate from or incorporated into the apparatus. mission. 
If a series of dots is used, the reagent dots may be a After landing, the frozen serum was removed within 8 
specific chemical, such as a dye which changes color with hours and transferred to a refrigerated transfer canister. The 
pH or with the progress of an enzymatic process or cascade. dried cards in stowage also were retrieved and all samples 
For example, such a dot could be capable of detecting 45 returned for postflight analysis. l b o  days after landing, the 
glucose through the action of the enzyme glucose oxidase. serum was thawed, the dried cards were rehydrated, and the 
In a preferred embodiment, the “dot” detects an antibody serum was extracted. The rehydration process involved 
mediated reaction which is specific to an analyte or a group removing the card from its plastic support frame, folding the 
of analytes. The antibody specifically binds to the analyte in card, placing the card inside a 10 ml tube, adding a set 
the absorbing matrix and initiates a cascade of &u- 5o quantity of distilled water, rotating the tubes for 5 minutes 
nochemical reactions which produce an observable change. and then extracting serum from the moistened paper by 
In another preferred embodiment of the device, the anti- compressing the paper with the plunger of the syringe and 
body may be loosely bound in the filter card 22, itself, and emptying the sample into the glass tube. 
therefore may pass through only with the passage of an The two sets of serum were analyzed simultaneously for 
analyte. Or, the antibody may be free in the filter card 22 or 55 the molecules shown in mG. 2. The majority of analytes 
the collection chamber 14 such that the antibody is bound to were measured in an automated CX 5 biochemistry unit 
a cell and does not pass through into the absorbent mahix 30 obtained from Beckman Instruments (Brea. Calif.) using a 
to initiate an identifying cascade. Any number of variations combination of amperometric and photometric methods. 
may be made to adapt test reagents for use in the present Most of the hormones are analyzed by radioimmunoassay 
invention. 
The invention will be more clearly understood with During the in-flight phase of the study, a ground-based 
reference to the following examples. control was run in which blood was drawn from two 
individuals using the same protocol and stored frozen or 
dried onto the card in the same way. The ground-based EXAMPLE 1 
In this experiment (Protocol l), blood was collected from 65 samples were subjected to conditions that were as similar to 
a crewmember on the Space Shuttle into both a vacutainer those of the in-flight samples as practical and were thawed 
and into the dried-blood collection device of the present or extracted and analyzed at the same time. 
35 
60 using commercially available methods. 
5,665,238 
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Data from the in-flight samples and ground-based controls 
were analyzed for mean, standard deviation, and coefficient 
of variation. Results from in-flight samples stored frozen 
were compared to results from the dried stored samples. The 
results are shown in FIG. 2. 
The dried-blood-chemistry method provided accurate cor- 
relation to frozen samples taken in flight. In addition, the 
dried blood chemistry results show, in ground-based studies, 
a high correlation with samples of the same serum tested 
fresh. 
EXAMPLE 2 
S a m  for this experiment (protocol 2) was collected and 
pooled. Known quantities of certain analytes were added to 
artificially increase the concentrations to allow for some 
degradation before the experiment was begun and to give a 
broad representative group of all of the subcomponents of 
serum. The pooled serum with “spiked” concentrations of 
certain molecules, including melatonin, angiotensin, antidi- 
uretic hormone, and atrial naturetic factor, was filter 
sterilized, and loaded into 17 syringes two days before 
launch. Thirteen of the syringes contained the exact volume 
known to be held by the cards from ground-based studies, 
one contained about 3 m l s  of the correct volume. and five 
contained about 7 mls of the known volume. The remaining 
two 5 ml syringes served as controls, and were stored frozen 
after the fluid had been placed on the cards. 
Each syringe was capped and wrapped in Teflon tape to 
prevent leakage if broken. Each syringe was labeled with a 
code number and had a matching storage card similarly 
labeled. The syringes and cards were stored inside a semi- 
rigid “NOMM” (thick cloth) bag inside of a -20” C. 
freezer. A drying box identical to the box used in the first 
experiment also was flown. 
On a flight day early to midway through the mission, the 
syringes and cards were removed from their protective bags 
and each syringe was emptied in sequence onto its paired 
storage card. The emptied syringes were discarded. The two 
remaining syringes were stored frozen and the time and date 
were recorded. The cards were transferred to the “drying 
box” and the drying box fan turned on for about 2 hours. At 
the end of this period, the “rip-top” desiccant and oxygen 
scavenger container were opened and the drying box closed. 
The entire drying box, with cards inside, were placed inside 
a second plastic bag. The bag was sealed, and the entire unit 
was stowed in a middeck locker for the duration of the 
mission. After landing, the samples were handled as 
described in Example 1. 
The dried-blood-chemistry method provided accurate cor- 
relation to frozen samples taken in-flight. In addition, the 
dried blood chemistry results showed, in ground-based 
studies, a high correlation with samples of the same serum 
tested fresh. 
The invention has been described in connection with a 
particular embodiment. One of skill in the art will appreciate 
that many modifcations may be made to the embodiment 
described herein without departing from the spirit of the 
present invention. Accordingly. the embodiment described 
10 
herein is illustrative only and is not intended to limit the 
scope of the present invention. 
We claim: 
1. Apparatus for passively collecting and separating into 
5 cellular and acellular fractions, a blood sample having a 
volume of up to about 20 milliliters, comprising: 
a housing having at least one opening therethrough for 
a fibrous filter dividing said housing into: 
receiving said blood sample; 
a blood sample collection chamber having a volume of 
at least about 1 ml, said blood sample collection 
chamber being in fluid communication with said 
opening; and 
a serum sample collection chamber; 
said fibrous filter comprising a iirst surface, substantially 
all of which fluidly communicates with a blood sample 
in said blood sample collection chamber, a second 
surface abutting and fluidly communicating with said 
serum sample collection chamber, and an intermediate 
portion having a given height sandwiched between and 
in fluid communication with both said first and said 
second surfaces; 
wherein said acellular fraction of said blood sample is 
filtered from said blood sample collection chamber, 
25 across said iirst surface, across said intermediate 
portion, and across said second surface into said serum 
sample collection chamber; and 
wherein said fibrous filter has a pore size below about 3 
microns and is coated with a mixture comprising 
between about 140% mannitol and between about 
0.1-15% albumin; and 
an absorbent matrix in fluid communication with said 
serum sample collection chamber. 
2. A method for passively separating into cellular and 
35 acellular fractions a blood sample having a volume of up to 
providing a housing comprising at least one opening 
therethrough for receiving a blood sample; 
providing a fibrous frlter comprising a first surface, sub- 
stantially all of which fluidly communicates with a 
blood sample in said blood sample collection chamber, 
a second surface abutting and fluidly communicating 
with said serum sample collection chamber, and an 
intermediate portion having a given height sandwiched 
between and in fluid communication with both said first 
and said second surfaces, wherein said fibrous filter has 
a pore size of about 3 microns or less and is coated with 
a mixture comprising between about 140% mannitol 
and between about 0.1-15% albumin; and 
separating said blood sample into cellular and acellular 
fractions by filtering said blood sample from said blood 
sample collection chamber, across said first surface, 
across said intermediate portion, and across said second 
surface into said serum collection chamber and onto an 
3. The method of claim 2 wherein said blood sample 
15 
20 
30 
about 20 milliliters, comprising the steps o f  
45 
50 
55 absorbent matrix. 
comprises a volume of between about 1-20 milliliters. 
* * * * *  
